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Introduction
SGLT2 inhibitors (SGLT2i) are unique antidiabetic drugs that promote urinary glucose loss and increase 
the urinary threshold for glucose reabsorption. As a result, plasma glucose levels are reduced and overall 
glycemic control is improved (1, 2). Intriguingly, SGLT2i, including canagliflozin (CANA), have recent-
ly been shown to reduce cardiovascular and all-cause mortality in type 2 diabetes (T2D) (3) and may 
improve hepatic steatosis and nonalcoholic fatty liver disease (4). The cellular actions of  SGLT2i are 
distinct from those of  other medications for T2D, such as insulin sensitizers and insulin secretagogues, 
which reduce blood glucose but increase glucose uptake and promote weight gain. By contrast, SGLT2i 
act in an insulin-independent manner to cause modest weight loss, promote fatty acid oxidation and 
ketogenesis, and increase hepatic glucose production (5–7), even after a single dose (8). The unique 
induction of  fatty acid oxidation and ketogenesis by SGLT2i may contribute to not only beneficial out-
comes, but also ketoacidosis reported with this medication class (9, 10).
Urinary glucose excretion has been proposed to mediate weight loss effects of  SGLT2i but cannot fully 
account for the observed weight loss (11). In contrast to diet-induced weight loss, there is no reduction in 
energy expenditure during SGLT2i-induced weight loss (11), potentially as a result of  increased lipid oxida-
Pharmacologic inhibition of the renal sodium/glucose cotransporter-2 induces glycosuria and 
reduces glycemia. Given that SGLT2 inhibitors (SGLT2i) reduce mortality and cardiovascular risk 
in type 2 diabetes, improved understanding of molecular mechanisms mediating these metabolic 
effects is required. Treatment of obese but nondiabetic mice with the SGLT2i canagliflozin (CANA) 
reduces adiposity, improves glucose tolerance despite reduced plasma insulin, increases plasma 
ketones, and improves plasma lipid profiles. Utilizing an integrated transcriptomic-metabolomics 
approach, we demonstrate that CANA modulates key nutrient-sensing pathways, with activation 
of 5′ AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin 
(mTOR), independent of insulin or glucagon sensitivity or signaling. Moreover, CANA induces 
transcriptional reprogramming to activate catabolic pathways, increase fatty acid oxidation, reduce 
hepatic steatosis and diacylglycerol content, and increase hepatic and plasma levels of FGF21. Given 
that these phenotypes mirror the effects of FGF21 to promote lipid oxidation, ketogenesis, and 
reduction in adiposity, we hypothesized that FGF21 is required for CANA action. Using FGF21-null 
mice, we demonstrate that FGF21 is not required for SGLT2i-mediated induction of lipid oxidation 
and ketogenesis but is required for reduction in fat mass and activation of lipolysis. Taken together, 
these data demonstrate that SGLT2 inhibition triggers a fasting-like transcriptional and metabolic 
paradigm but requires FGF21 for reduction in adiposity.
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tion (5). Thus, the precise molecular mechanisms responsible for SGLT2i-mediated effects on metabolism 
and weight loss remain to be characterized.
Here, we utilize an integrated transcriptomic-metabolomics approach to identify molecular media-
tors of  CANA in nondiabetic mice with diet-induced obesity. We demonstrate that CANA modulates key 
nutrient-sensing pathways, with activation of  5′ AMP–activated protein kinase (AMPK) and inhibition of  
mechanistic target of  rapamycin (mTOR), without changing insulin or glucagon sensitivity or signaling. 
Moreover, CANA induces transcriptional reprogramming to activate catabolic pathways, increase fatty 
acid oxidation, reduce hepatic steatosis, and increase hepatic and plasma levels of  the hepatokine FGF21. 
FGF21 is an important coordinator of  fasting-induced metabolic responses and reduction in adiposity via 
increasing lipolysis, hepatic fatty acid oxidation, and ketogenesis. Given that these effects mirror many 
phenotypes induced by CANA, we hypothesized that FGF21 would be required for CANA action. Using 
FGF21-null mice, we demonstrate that FGF21 is not required for the metabolic switch toward a fasting-like 
catabolic state but is required to promote lipolysis and reduction in adiposity in response to SGLT2i.
Results
CANA reduces blood glucose, improves glucose tolerance, and causes a shift toward lipid utilization. To analyze the 
metabolic response to SGLT2 inhibition, and to dissect the effect of  weight loss in mediating these effects, 
3 groups of  mice were evaluated: (a) high-fat diet–fed (HFD-fed) ad libitum; (b) HFD plus CANA mixed 
in diet (25 mg/kg/d), provided ad libitum (CANA); and (c) HFD-fed mice fed such that they were weight 
matched (WM) with the HFD plus CANA group, achieved via 15%–30% caloric restriction. As expected, 
CANA treatment induced glycosuria (Figure 1A) and reduced fasting glucose (Figure 1B) as compared 
with HFD (P < 0.0001). While fasting glucose was also decreased in WM mice, the reduction was greater 
in magnitude in CANA-treated mice (P < 0.05). CANA also attenuated HFD-induced weight gain (Figure 
1C); weights of  WM mice were similar to those of  CANA-treated mice, as per study design. CANA-treated 
mice have improved oral glucose tolerance, with greater magnitude as compared with WM group (Figure 
1D). Insulin levels were similar in the fasting state in all 3 groups but were lower at 15 minutes after glucose 
gavage in CANA-treated mice as compared with both control and WM mice (Figure 1E). Interestingly, glu-
cose-stimulated GLP-1 levels were reduced in WM mice but were maintained in CANA-treated mice at lev-
els similar to those of  HFD-fed mice (Figure 1F). By contrast, fasting glucagon levels did not differ between 
groups (Figure 1G). Insulin sensitivity, assessed by insulin tolerance testing, did not differ between groups 
(Figure 1H). Similarly, despite lower fasting glucose with CANA, there was no change in glycemic response 
to glucagon or pyruvate (Supplemental Figure 1, A and B; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.123130DS1). As expected, water intake was significantly 
increased in CANA-treated mice (Figure 1I), likely due to increased urine output through osmotic diuresis.
We hypothesized that the reduction in glucose carbon sources through glycosuria would trigger uti-
lization of  alternative fuel sources, such as fatty acids and amino acids. Indeed, metabolic cage analysis 
demonstrated persistently low respiratory exchange ratio (<0.7) in CANA-treated mice, even during the 
fed state (Figure 1J), implying increased lipid or ketone utilization, as compared with both HFD and WM 
mice. O2 consumption, heat production, physical activity, and food intake were unchanged (Supplemental 
Figure 1, C–G). Increases in whole-body fatty acid mobilization and utilization in CANA-treated mice 
were also supported by a trend to increased free fatty acids (Figure 1K) and a significant increase in the 
serum ketones acetoacetate and 3-hydroxybutyrate (as measured by LC/MS) (Figure 1L and Supplemental 
Figure 1H). Serum valine, leucine, isoleucine, and total branched chain amino acids (BCAA) tended to 
decrease in CANA-treated mice (Supplemental Figure 1, H and I).
To further assess weight-dependent versus weight-independent effects of  CANA treatment, we also 
analyzed in vivo metabolism in lean mice fed a low-fat diet (LFD) (Supplemental Figure 2). Similar 
to HFD-fed mice, CANA induced glycosuria, reduced fasting glucose, improved glucose tolerance, 
increased whole body lipid oxidation, and increased serum β-hydroxybutyrate levels. By contrast, CANA 
did not change body weight or adipose tissue mass in LFD-fed mice. Thus, metabolic responses to CANA 
occur even in the absence of  weight loss.
CANA reduced hepatic steatosis and shifts fuel utilization from carbohydrates toward catabolic lipid metabo-
lism and ketogenesis. To better understand the effect of  CANA at a tissue level, we analyzed liver lipid 
metabolism. H&E staining revealed a significant reduction in hepatic steatosis in CANA-treated mice 
(Figure 2A); all mice in HFD group had moderate to severe steatosis, while 36% of  CANA-treated mice 
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had no steatosis (P < 0.0001 vs. WM and HFD, Figure 2B). Surprisingly, there was no change in hepatic 
triglyceride content, as assessed by lipase hydrolysis and glycerol measurement, in CANA-treated mice, 
despite a significant 44% reduction in WM mice (P < 0.01 vs. HFD) (Figure 2C). To identify lipid spe-
cies differing between HFD and CANA mice, liver samples were subjected to lipidomic analysis by LC/
MS. Again, there were no changes in triglyceride content in CANA-treated mice relative to HFD-fed 
Figure 1. Canagliflozin reduces blood glucose, improves glucose tolerance, and causes a shift toward lipid utilization. (A) Urinary glucose in HFD, 
weight matched (WM), and HFD + CANA (CANA) after an overnight fast, after 8 weeks of treatment (n = 8–11/group). (B) Blood glucose after a 16-hour 
fast (n = 8/group). (C) Body weight (n = 12/group). (D) Oral glucose tolerance (2 g/kg, n = 12/group). (E) Plasma insulin, fasting and 15 minutes after 
glucose gavage (n = 8/group). (F) Plasma glucagon-like peptide-1 (GLP-1), fasting and 15 minutes after glucose gavage (n = 8/group). (G) Fasting plasma 
glucagon (n = 6/group). (H) Insulin tolerance (0.75 U/kg, n = 8/group). (I) Water intake (n = 6–12/group). (J) Respiratory exchange ratio (n = 6–12/group). 
(K) Serum-free fatty acids (4-hour fast, n = 11–12/group). (L) Serum ketones (LC/MS, n = 7–8/group). P values (1- or 2-way ANOVA). *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001 in HFD vs. CANA. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 in WM vs. CANA; and $P < 0.05, $$P < 0.01, $$$P < 
0.001, $$$$P < 0.0001 in WM vs. HFD. 
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mice or WM mice, nor in other lipid species, including lysophosphatidylethanolamine, lysophospha-
tidylcholine, phosphatidylinositol, sphingomyelin, cholesterol ester, phosphatidylethanolamine, and 
phosphatidylcholine (Supplemental Figure 3A). However, there was a significant 43% reduction in total 
diacylglycerol species (Figure 2D). In addition, there was a significant reduction in triglyceride species 
containing 0, 2, 3, or 4 double bonds and a significant increase in triglycerides containing 11 double 
bonds in CANA-treated mice (Figure 2E). While the reduction in unsaturated and monounsaturated 
species was observed in both WM and CANA-treated mice, the increase in polyunsaturated species 
was unique to CANA-treated mice. Consistent with serum patterns, 3-hydroxybutyrate was increased 
by 3.5-fold in CANA-treated mice but did not differ in WM mice, indicating weight loss–independent 
response (P < 0.001 for both) (Figure 2F). Cholesterol content was reduced in CANA-treated mice (27% 
decrease, P < 0.05 vs. HFD), but not in WM mice (Figure 2G).
We next assessed the effect of  CANA on other metabolic pathways. Hepatic content of  glycogen, the 
anabolic storage form of  glucose, was reduced in CANA-treated mice in comparison to both HFD-fed and 
WM mice (55% reduction vs. HFD, 53% reduction vs. WM, P < 0.05 for both) (Figure 2H). Tissue metab-
olomics analysis revealed a robust reduction in hepatic content of  multiple other metabolites, with 163 of  
334 measured metabolites significantly altered (Figure 2I). Carbohydrate-derived metabolites, including 
glucose/fructose/galactose and 1,5-AG/1-deoxyglucose, were significantly reduced, potentially due to uri-
nary losses of  both glucose and 1,5-AG with SGLT2i (Figure 2, J and K) (12). UDP-GlcNAc, the key end-
point of  the hexosamine biosynthesis pathway, and multiple glycolytic metabolites were also significantly 
lower in CANA-treated mice (Figure 2J). By contrast, N-carbonyl β-aminoisobutyric acid (BAIBA) and the 
lipidated amino acid oleoyl phenylalanine were increased; both of  these have been shown to increase ener-
gy expenditure through fatty acid oxidation and uncoupling, respectively (13, 14). Metabolites upregulated 
in CANA-treated mice included FAD+, AMP, ADP, NADP+, UMP, and the ketone 3-hydroxybutyric acid 
(Figure 2I). In addition, multiple long-chain acylcarnitine species were increased in liver, including C10, 
C12, C14, C16, and C18:2 (Supplemental Figure 3B). Collectively, these data indicate an overall reduc-
tion in glucose-derived metabolites, including glycogen, and a parallel increase in catabolic intermediates, 
including ketones. These patterns were not observed in WM mice, indicating that the effects of  CANA on 
hepatic metabolism were weight independent.
CANA decreases mTOR signaling and activates AMPK without altering insulin and glucagon signaling. We 
next examined effects of  CANA on hepatic signaling pathways that regulate lipid oxidative metabolism. 
CANA has recently been shown to activate hepatic AMPK through inhibition of  mitochondrial complex I 
(15); in agreement, our metabolomics analysis demonstrated a significant increase in hepatic AMP (Figure 
2I). Thus, we hypothesized that AMPK activation might contribute to increases in whole-body fatty acid 
oxidation and hepatic gene expression. Indeed, AMPK phosphorylation (threonine 172) was increased by 
10-fold and 20-fold in CANA-treated and WM mice, respectively (Figure 3A). By contrast, phosphorylation 
of  the downstream effector acetyl CoA carboxylase (Acc) was not increased, potentially due to significantly 
reduced total Acc protein (P < 0.05 vs. HFD) (Figure 3A). While lean mice treated with CANA had similar 
increases in lipid oxidation, AMPK and ACC phosphorylation were not increased (Supplemental Figure 
4). Thus, AMPK was likely not responsible for CANA-specific increases in FA oxidation and ketogenesis.
mTOR is a cellular energetic sensor often regulated inversely with AMPK. Indeed, there was a 
56% decrease in hepatic phosphorylation of  the mTOR downstream substrate S6 upon refeeding in 
CANA-treated mice (P < 0.05) (Figure 3A) but not in WM controls, suggesting weight-independent 
reduction in mTOR signaling.
To determine whether the metabolic response to CANA was linked to alterations in tissue insulin or 
glucagon signaling, we analyzed multiple downstream signaling molecules using Western blot analysis 
of  liver harvested in the fasting and refed states. There were no significant changes in phosphorylation 
of  cyclic-AMP response elements (CREB), Akt, or forkhead box protein O1 in CANA-treated mice with 
fasting or refeeding (Figure 3A).
Given that diacylglycerol, an important mediator of  hepatic insulin resistance, was reduced by CANA, 
we also assessed hepatic insulin signaling after acute inferior vena cava injection. Insulin increased phos-
phorylation of  insulin receptor, Akt, and Gsk3, as expected; while serine phosphorylation of  Akt was mod-
estly higher in CANA-treated mice (24% increase, P < 0.05), there were no significant differences in insulin 
receptor, Akt threonine phosphorylation, or downstream glycogen synthase kinase 3 (GSK3) phosphory-
lation (Figure 3B). Thus insulin action is unlikely to be the driver of  CANA-induced metabolic changes.
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CANA triggers transcriptional reprogramming and yields a fasting-like metabolic response and requires fatty acid 
oxidation for successful metabolic adaptation. To better understand the molecular mechanisms mediating the 
effect of  CANA on hepatic metabolism, we performed microarray-based transcriptomic analysis in all 3 
treatment groups. CANA treatment induced robust changes in hepatic gene expression (2522 genes differ-
entially expressed in CANA-treated mice vs. HFD, nominal P < 0.05) (Supplemental Figure 5A). Sixteen 
Figure 2. Canagliflozin reduced hepatic steatosis and shifts fuel utilization from carbohydrates toward catabolic lipid metabolism and ketogenesis. (A) 
Representative H&E-stained liver section. Original magnification, ×20. (B) Quantification of hepatic steatosis. Grade 0 indicates no steatosis, 1 indicates 
<33%, 2 indicates 33–66%, and 3 indicates >66% of ×20 field. (C) Hepatic triglyceride (n = 11–12/group). (D) Hepatic diacylglycerol (LC/MS). (E) Triglyceride 
content stratified by number of double bonds, normalized to the HFD group (LC/MS). (F) Hepatic ketones (n = 7–8/group). (G) Hepatic cholesterol (n = 7–8/
group). (H) Hepatic glycogen (n = 7–8/group). (I) Volcano plot of hepatic metabolites altered by CANA, in comparison with HFD. (J and K) Hepatic metabo-
lites (LC/MS, n = 7–8/group). P values (1-way ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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transcripts were significantly altered in all comparisons (P < 0.05); most of  these were noncoding tran-
scripts. Pathway analysis of  CANA-mediated changes revealed reduced cholesterol, de novo lipogenesis, 
steroid hormone, and vitamin A and D synthesis and increased tricarboxylic acid (TCA) cycle and electron 
transport chain pathways (all P < 0.01) (Supplemental Figure 5B). Genes regulating de novo lipogenesis 
(Acc, Fasn, and Scd1) were downregulated, as were genes regulating cholesterol uptake (Pcsk9) and syn-
Figure 3. CANA decreases mTOR signaling and activates AMPK without altering insulin and glucagon signaling. (A) Phosphorylation of 5′ AMP-activated 
protein kinase (AMPK, Thr172), acetyl CoA carboxylase (ACC, Ser79), ribosomal protein S6 (Ser240), cAMP response element binding protein (CREB, Ser133), 
Akt (Thr308, Ser473), and FOXO1 (Ser256) after overnight fast with or without 4-hour refeeding. (B) Phosphorylation of insulin receptor IRβ (Y1135/36), Akt 
(Thr308, Ser473), GSK3 (Ser21/9), and FOXO1 (Ser256) in fasted or insulin-stimulated mice (5 minutes). n = 3–5/group. P values (1-way ANOVA). *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001.
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thesis (Hmgcr, Lss, and Hmgcs1) (Figure 4A). While the glycolytic genes Gck, Pgam1, Gapdh, and Pklr were 
downregulated, TCA cycle and electron transport chain genes were upregulated, with increases in Sucla2, 
Suclg1, Etfdh, Cycs, Cox5b, and Etfa (Figure 4A). qPCR of  selected genes confirmed expression data (Figure 
4, B–F). Interestingly Pdk4 was highly upregulated (Figure 4B), potentially contributing to reduced entry of  
glucose carbons into the TCA cycle. Ppp1r3c, a key mediator of  glycogen synthesis, was also downregulated 
by 80% in CANA-treated mice (P < 0.05 and P < 0.01 in CANA vs. HFD and WM, respectively, Figure 
4B). By contrast, expression of  the gluconeogenic gene G6pc was increased in CANA (P < 0.05, Figure 4B). 
Chrebp-β, a key mediator of  both carbohydrate metabolism and lipogenesis, was significantly reduced by 
50% (P < 0.05 vs. HFD, Figure 4C). Notably, the effect of  CANA treatment was consistently greater than 
that of  limiting HFD-associated weight gain, indicating transcriptional effect to reduce glucose storage/ 
metabolism and lipid synthesis, independent of  weight loss.
Intriguingly there was no change in expression of genes encoding mitochondrial β-oxidation or ketogenesis 
enzymes, including Cpt1a, Acadm, Acadl, Acadvl, and Hmgcs2 (Figure 4D), while the microsomal fatty acid oxi-
dation gene Cyp4A14 tended to increase (10-fold) in CANA (Figure 4E). There was a 2.2- and 3.6-fold increase 
in the regulatory nuclear receptor Ppara and its coactivator Pgc1α, respectively (Figure 4F). Transcription factor–
binding site analysis identified Ppara as a potential transcription factor contributing to expression of upregulated 
genes in CANA-treated mice versus HFD-fed and WM mice (nominal P < 0.05) (Supplemental Figure 5C).
To test the requirement for fatty acid oxidation in CANA-induced metabolic responses, we adminis-
tered etomoxir, an inhibitor of  carnitine palmitoyl transporter 1 (CPT1), the major transporter of  fatty acids 
into mitochondria. CANA-treated mice were intolerant of  etomoxir, as indicated by (a) the development of  
hypoglycemia 60 minutes after etomoxir administration (P < 0.001 for CANA vs. HFD, Supplemental Fig-
ure 6A) and (b) subsequent 100% mortality (P < 0.03 for CANA vs. HFD, Supplemental Figure 6B). Thus, 
these data support the hypothesis that fatty acid oxidation is required for successful adaptation to CANA.
CANA triggers coordinated interorgan nutrient repartitioning from adipose tissue. CANA-induced increases in 
fatty acid oxidation and ketogenesis could reflect observed reductions in glucose availability and metabo-
lism as well as increased systemic flux of  lipids from adipose tissue linked to reduced insulin levels (Figure 
1E). Indeed, subcutaneous and gonadal fat mass were reduced in both CANA-treated and WM mice, while 
brown adipose weight was reduced only in CANA-treated mice (Figure 5A and Supplemental Figure 4A). 
We further observed a significant reduction in the mean size of  subcutaneous adipocytes (Figure 5, B and 
C). To test whether adipose lipolysis could contribute to these findings, we stimulated mice in vivo with the 
β-3 adrenergic agonist CL-316243. Free fatty acid release in response to CL-316343 was increased by 3-fold 
in CANA-treated mice, as compared with 2-fold increase in HFD-fed mice (P < 0.05 between groups, Fig-
ure 5D). There was no increase in Ucp1 expression or other markers of  browning (Figure 5E), there was no 
change in adiponectin levels (Supplemental Figure 7B), and there were no differences in thermogenic respons-
es to cold exposure between groups (Supplemental Figure 7C and Supplemental Methods). Quantification of  
islet size revealed a significant reduction in both CANA-treated and WM mice (Supplemental Figure 7, D 
and E). Thus, adipose effects were more pronounced in CANA-treated mice than in WM controls, supporting 
CANA-mediated promotion of  white adipose lipolysis, potentially mediated by reduced insulin levels.
CANA increases hepatic and serum FGF21. Since CANA had marked effects suggesting partitioning of  
nutrients away from adipose tissue and toward liver for oxidation, we hypothesized that the hepatokine 
FGF21 could be orchestrating CANA-mediated whole-body metabolic shifts. Indeed, CANA-treated 
mice had significant increases in both hepatic Fgf21 mRNA expression (3.9-fold, P < 0.05, Figure 6A) 
and fasting serum FGF21 levels (2.2-fold higher than HFD-fed mice: 6223 ± 373 vs. 2784 ± 536 pg/ml, 
P < 0.05); increased plasma FGF21 was not observed in WM controls (Figure 6B). These patterns were 
potentially mediated by increased Ppara and Pgc1α, respectively (Figure 4F). Taken together, these data 
indicate that CANA triggers a fasting-like catabolic switch, increasing adipose lipolysis, hepatic fatty 
acid oxidation, and ketogenesis, potentially via FGF21-dependent mechanisms.
FGF21 is not required for CANA-induced effects on glucose tolerance, hepatic lipid metabolism, and steatosis. FGF21 
is a fasting-induced hepatokine that can trigger whole-body metabolic switch from glucose to fatty acid utiliza-
tion (16). Given that both plasma concentration and hepatic expression of Fgf21 were increased in response to 
CANA, we tested the requirement for FGF21 in mediating metabolic effects of CANA using mice fed a 60% 
HFD. HFD-fed FGF21 whole-body-KO (FGF21-KO) mice and WT controls were treated with CANA for 6 
weeks. CANA treatment induced a massive increase in urine glucose, as expected, but glycosuria was slightly 
greater in FGF21-KO mice (P < 0.0001, CANA-treated WT vs. FGF21 KO) (Figure 7A). FGF21-KO and WT 
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mice had a similar reduction in fasting blood glucose in response to CANA (Figure 7B). Although FGF21-KO 
mice were more glucose intolerant than WT mice at baseline, they had similar-magnitude improvement with 
CANA (Figure 7C). Insulin sensitivity was not affected by CANA in either genotype (Figure 7D).
Since FGF21 is an important mediator of  whole-body and hepatic adaptation to ketogenic diet (16), 
we tested whether FGF21 is also required for CANA-induced ketogenesis. Interestingly, CANA lowered 
the respiratory exchange ratio by a similar magnitude in both FGF21-KO and WT mice (Figure 7E). Like-
wise, CANA induction of  β-hydroxybutyrate was similar in both FGF21-KO and WT mice (Figure 7F). 
Similar to the original cohort, there was no change in O2 consumption, heat production, physical activity, 
or food intake in either WT or FGF21-KO mice (Supplemental Figure 8, A–E). At a tissue level, hepatic 
steatosis was worse in FGF21-KO mice at baseline, but CANA improved steatosis to a similar extent in 
both WT and FGF21-KO mice (Figure 7G).
As expected, Fgf21 expression was absent in FGF21-KO mice (Supplemental Figure 8F). Hepatic 
expression of  Ppara and G6pc was higher in FGF21-KO mice at baseline, but there was no additional 
Figure 4. Canagliflozin triggers transcriptional reprogramming, reflecting a fasting-like metabolic state. (A) Heatmap of individual genes within selected 
pathways, colored by log2 fold change. (B–F) qPCR validation of selected genes (n = 3–5/group). P values (1-way ANOVA). *P < 0.05, **P < 0.01.
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incremental response to CANA (Figure 7, H and I). Expression of  glucose and lipogenic regulatory genes, 
including Gck, Chrebp-β, and Fasn, was similarly reduced in both WT and FGF21-KO mice treated with 
CANA (Figure 7I). Thus, CANA-induced increases in whole-body fatty acid metabolism, ketogenesis, and 
hepatic transcriptional reprograming are independent of  FGF21.
FGF21 is required for effects of  CANA on body weight and induction of  adipose lipolytic transcriptional regulation. 
WT mice treated with CANA had lower body weight as compared with untreated controls. FGF21-KO mice 
treated with CANA had a trend toward higher body weight as compared with WT mice treated with CANA 
(Figure 8, A and B). Moreover, there was a paradoxical increase in gonadal white adipose (gWAT) tissue 
weight in FGF21-KO mice treated with CANA (Figure 8C), despite similar trends for CANA to reduce sub-
cutaneous weight in both genotypes (Figure 8C). Adipocyte size in gWAT of  untreated WT and FGF21-KO 
mice had similar distributions; by contrast, CANA reduced mean adipocyte size in WT mice but actually 
Figure 5. Canagliflozin triggers coordinated interorgan nutrient repartitioning from adipose tissue. (A) Tissue weight after 9 weeks of CANA (n = 12/
group). gWAT, perigonadal; SC, subcutaneous; BAT, brown adipose tissue. (B) Representative H&E-stained subcutaneous adipose section. Original 
magnification, ×40. (C) Quantification of adipocyte size (n = 8/group). (D) Percentage change in free fatty acids after CL-316243 injection (0.1 mg/kg, n 
= 6/group). (E) qPCR analysis of subcutaneous adipose gene expression after 4 hour fast (n = 6/group). P values (1-way ANOVA). *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001.
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increased mean adipocyte size in FGF21-KO mice (Figure 8, D and E). Indeed, mean adipocyte area was 
increased by 1.6-fold in CANA-treated FGF21-KO versus CANA-treated WT mice (P < 0.05, Figure 8F).
FGF21 can act in the central nervous system to induce sympathetic nervous system activation, energy 
expenditure, and weight loss (17, 18). Sympathetic activation is also required for the maximal weight loss 
effect of  a ketogenic diet (19). As sympathetic activation is critical for induction of  lipolysis in white adi-
pose tissue, we hypothesized that defective lipolysis might contribute to a reduced CANA effect on weight 
loss, adiposity, and cell size in FGF21-KO mice. Indeed, expression of  β-3 adrenergic receptor (β3ar) and 
adipose triglyceride lipase (Atgl) was upregulated by 2.2-fold in WT mice treated with CANA. However 
this upregulation was abolished in FGF21-KO mice treated with CANA (P < 0.05, Figure 8G). In addi-
tion, Atgl was also significantly upregulated by 3.6-fold at the protein level (P < 0.05, Figure 8I). There 
was no change in mRNA expression of  other lipolytic enzymes, such as hormone-sensitive lipase (Hsl) or 
monoglyceride lipase (Mgll). In addition, expression of  the deiodinase type 2 (Dio2), another target of  sym-
pathetic activity, was reduced by 77% in FGF21-KO mice, in both CANA-treated and untreated states (P 
< 0.05, Figure 8G). Gene expression analysis also revealed differential regulation by CANA for regulators 
of  lipogenesis, with upregulation of  Acc and Dgat1 by 2.2- and 2.7-fold in WT mice but no induction in 
FGF21-KO mice; similar trends were observed for Chrebp (Figure 8H). Interestingly, there was no alter-
ation in expression of  Pparg (Supplemental Figure 9A), but expression of  Ppard was reduced in FGF21-KO 
mice in both treated and untreated states (P < 0.05, Figure 8H). In addition, phosphorylation of  HSL, a 
key regulator of  lipolysis, was significantly higher in CANA-treated mice (10-fold vs. untreated, P < 0.05). 
Notably, the CANA-induced increase in HSL phosphorylation was abolished in FGF21-null mice (HSL 
phosphorylation 87% lower in CANA-treated FGF21-null vs. WT mice, P = 0.06, Figure 8I). Thus, Fgf21 
appears to be essential for CANA-induced reduction of  adipose tissue mass, adipocyte cell size, and activa-
tion of  lipolysis programming at a transcriptional and protein level.
Discussion
SGLT2i have recently been demonstrated to reduce both overall and cardiovascular mortality in T2D (3). While 
alterations in both hemodynamic and metabolic regulation have been hypothesized as mediators of these ben-
eficial effects, the precise mechanisms remain unknown. Identification of molecular regulators governing the 
metabolic effect of cellular and systemic glucose reduction will not only facilitate our understanding of SGLT2i 
pharmacology, but may also contribute to development of novel therapies or predictors of responses.
We now demonstrate that urinary glucose loss through SGLT2i not only reduces blood glucose and 
improves glucose tolerance, but also triggers a robust metabolic switch from using glucose carbon as fuel 
toward a fasting-like state, with increased fatty acid utilization and ketogenesis. This fuel mobilization also 
reduced liver steatosis, lipogenesis and adipose tissue mass. Importantly, these findings were not observed in 
weight-matched controls but were consistent even in lean animals, indicating these effects are independent of  
weight loss and instead reflect additional metabolic consequences of  SGLT2i and urinary glucose loss.
With marked reductions in glucose availability and utilization, alternative fuel sources must be uti-
lized to supply the TCA cycle during fasting, such as amino acids (20–22) or fatty acids. We found only 
modest reductions in all 3 circulating BCAA, and no significant changes in expression of  genes regulating 
Figure 6. Canagliflozin increases hepatic and serum FGF21. (A) Hepatic expression of FGF21 after a 4-hour fast (n = 
3–5/group). (B) Fasting serum FGF21 level, as measured by ELISA (n = 6/group). P values (1-way ANOVA). *P < 0.05, 
**P < 0.01, ***P < 0.001.
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amino acid catabolism. Instead, our data point to an important role for lipid metabolism as mediator of  
the hepatic and systemic metabolic shift observed with CANA, as indicated by altered lipid composition, 
increased ketones, upregulation of  genes promoting lipid oxidation and TCA cycle activity, and reduction 
in lipogenic gene expression. Interestingly, there was an increase in polyunsaturated lipids, particularly for 
triglycerides with >9 double bonds. This pattern, which was unique to CANA and not observed in WM 
mice, is similar to the serum triglyceride composition previously linked to metabolic health and decreased 
progression from impaired fasting glucose to T2D in humans (23). Moreover, CANA reduced hepatic levels 
of  diacylglycerols, previously linked to hepatic insulin resistance (24).
Glucose-responsive nutrient sensors could contribute to metabolic shifts induced by CANA. For exam-
ple, CANA reduced hepatic levels of  UDP-GlcNAc, the end-product of  the glucose-sensing hexosamine 
biosynthetic pathway. However, we observed no difference in GlcNAc posttranslational protein modifica-
Figure 7. FGF21 is not required for CANA-induced improvement in glucose tolerance, activation of fatty acid oxidation and ketogenesis, reduction in 
hepatic steatosis, and transcriptional reprogramming. (A) Urinary glucose after 6 weeks of CANA (n = 6–9/group). (B) Blood glucose, random fed (n = 7–9/
group). (C) Intraperitoneal glucose tolerance test (1 g/kg) after overnight fast (n = 7–9/group). (D) Insulin tolerance test (n = 7–9/group). (E) Respiratory 
exchange ratio (n = 7–9/group). (F) Serum ketones after 16-hour fast (n = 7–9/group). (G) Quantification of hepatic steatosis by histology scoring. (H and I) 
qPCR of regulatory genes for fatty acid oxidation, ketogenesis, glucose metabolism, lipogenesis, and gluconeogenesis in liver (n = 6–8/group). P values (1- 
or 2-way ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; @@P < 0.01 in WT vs. FGF21 KO; !P < 0.05 in WT vs. WT + CANA; #P < 0.05 in FGF21 
KO vs. FGF21 KO + CANA; $P < 0.05 in WT+ CANA vs. KO + CANA.
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tion (data not shown) (25). Chrebp-β, which can be activated by glucose to increase glycolysis and lipogene-
sis, was robustly suppressed with CANA. However, ChREBP suppression alone is not sufficient to activate 
fatty acid oxidation, ketogenesis, and gluconeogenesis (26, 27).
AMPK is a nutrient sensor coordinating the balance between anabolism and catabolism. Intracellu-
lar AMP content and hepatic AMPK phosphorylation were increased with CANA in obese mice. While 
increased activation of  AMPK was also observed by Hawley et al., AMPK was not required for CANA 
Figure 8. FGF21 is required for CANA-induced reduction in adipocyte size and activation of sympathetic and lipolysis-related gene expression. (A) 
Body weight (n = 7–9 animals/group). (B) Body weight after 6 weeks of treatment (n = 7–9 animals/group). (C) Tissue weight after 6 weeks of CANA 
treatment (n = 7–9/group). (D) Representative H&E-stained gonadal adipose section. Original magnification, ×10; scale bar: 100 μM. (E) Adipocyte 
area histogram (n = 7–9/group). (F) Mean adipocyte size (n = 7–9/group). (G and H) qPCR of genes regulating oxidative phosphorylation, sympathetic 
activation, and adipose function (n = 6–7/group). (I) Western blot and quantification of hormone-sensitive lipase (HSL) (Ser660 and total protein) and 
adipose- triglyceride lipase (ATGL) (n = 6/group). P values (1 or 2-way ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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effects to reduce glucose and increase fatty acid oxidation (15). In agreement, our data indicate that AMPK 
activation by CANA is not consistently linked to metabolic efficacy of  the drug. For example, AMPK is 
not activated in lean mice treated with CANA, despite action of  the drug to reduce glucose and activate 
lipid oxidation; conversely, AMPK is similarly activated in weight-matched and CANA-treated obese mice, 
despite differential metabolic responses. Such context-specific activation of  AMPK dissociated from met-
abolic response indicates that it is not likely the major mediator of  CANA-induced metabolic responses.
We also considered the possible effect of  hormonal responses as mediators of  CANA-mediated meta-
bolic adaptations. Insulin levels were reduced in CANA-treated mice, and hepatic signaling was not mark-
edly altered in CANA-treated mice, suggesting insulin action was not responsible for metabolic adapta-
tions. SGLT2i treatment increases glucagon levels in humans with T2D, potentially via direct effects in α 
cells (5, 8, 28). However, plasma glucagon levels, glucagon responsiveness, and tissue activation of  CREB 
were not altered in our model. Consistent with our findings, plasma glucagon is unchanged with SGLT2i 
treatment in some studies of  rodents with either T1D or T2D (29). Collectively, these data indicate that 
increased glucagon signaling is not a uniform effect of  SGLT2i and that neither insulin nor glucagon are 
sufficient to coordinate SGLT2i-induced metabolic shifts in nondiabetic rodents.
Our data indicate potent effects of CANA to increase hepatic expression of FGF21, yielding increases in 
serum FGF21 levels even higher than those in HFD-fed mice, findings consistent with increased FGF21 in 
SGLT2i-treated mice recently reported by Xu et al. (30). FGF21 is activated in response to prolonged fasting 
or nutritional ketosis (31), in part via peroxisome PPARα binding to its promoter, and is required for maximal 
induction of adipose tissue lipolysis, hepatic fatty acid oxidation, ketogenesis, and gluconeogenesis (31, 32). 
FGF21 can also induce thermogenesis by triggering a futile cycle of lipogenesis, lipolysis, and oxidative phos-
phorylation in adipose tissue. This can occur via either adipose FGFR/β-klotho receptor signaling or centrally 
mediated activation of the sympathetic nervous system (17, 18, 33–37). Since these effects mirror multiple met-
abolic effects of SGLT2i, we hypothesized that FGF21 would also mediate CANA-induced metabolic effects.
Interestingly, we now report that FGF21 is not required for either CANA-mediated improvement in glu-
cose tolerance or induction of  a broad fasting-like catabolic transcriptional program. At a whole-body level, 
CANA similarly lowered RQ in both WT and FGF21-KO mice, indicating similar shifts toward lipid metabo-
lism. Moreover, plasma ketones are similarly increased in FGF21-KO mice treated with CANA. Both PPARα 
and PPAR γ coactivator 1-α (PGC1α) were increased in liver, independent of  FGF21. Thus, CANA-induced 
increases in whole-body and hepatic lipid oxidative metabolism, ketogenesis, and transcriptional regulation 
are FGF21-independent. CANA-mediated reduction in glycogen could play a direct role in activating ketone 
synthesis (38) and regulating sympathetic activation of  adipose lipolysis (39); reductions in Tor-dependent 
signaling could also activate PPARα-dependent ketogenesis (40). Moreover, acetylation or other posttransla-
tional modifications of  mitochondrial proteins or transcription factors could play an additive role to activate 
PPARα, fatty acid oxidation, and ketogenesis (41, 42). Likewise, the direct effect of  intermediary metabolites, 
especially glucose, on chromatin structure could contribute to the control of  cellular function and metabolism 
(43). Testing these possibilities will be important in the future.
By contrast, our data indicate that FGF21 is required for weight loss and effects of  SGLT2i on adipocyte 
metabolism. While CANA reduced adipocyte size, FGF21-null mice had no weight loss, and adipose tissue 
and cell size actually increased in response to CANA. At a transcriptional level, FGF21-null mice failed to 
upregulate expression of  the β3-adrenergic receptor or Atgl in response to CANA. Similarly, ATGL pro-
tein expression and Hsl phosphorylation failed to increase in CANA-treated FGF21-null mice, suggesting 
impaired sympathetic and lipolytic activity. This is not surprising as FGF21 increases oxidative metabolism, 
browning, and lipolysis in white adipose tissue (18, 31, 44) via either direct interaction with β-klotho or via 
activation of  the sympathetic nervous system or immune cells (17). Interestingly, recent studies have also 
demonstrated that sympathetic activation is also critical for weight loss in the context of  nutritional keto-
sis (19). Future work will identify whether FGF21 per se, or FGF21-dependent activation of  sympathetic 
nervous system signaling, is required to mediate weight loss with SGLT2i therapy. We acknowledge limita-
tions of  our study. First, measures of  in vivo physiology together with metabolomic and transcriptomic data 
suggest that CANA induces shifts in nutrient metabolism but do not permit direct assessment of  metabolic 
fluxes. While the dose of  CANA used in our study yields plasma drug concentrations (10 μg/ml) that are 
similar to levels achieved in humans after a typical 300 mg clinical dose (3.4–4.6 μg/ml) (data provided by 
Janssen Pharmaceuticals), findings in mouse models may not mirror dose-response relationships in humans. 
Moreover, findings in rodent models may not be fully generalizable to human pathophysiology.
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In summary, we found that reduction in whole-body and tissue glucose via treatment of  diet-induced 
obese mice with the SGLT2i CANA induced robust metabolic and transcriptomic reprogramming. Mod-
ulation of  the PPARα-FGF21 axis, reduced insulin concentrations, and altered activity of  cellular nutrient 
sensors yield a fasting-like catabolic state. Hepatic reprogramming of  metabolism and transcription does not 
require FGF21, but FGF21 is required for CANA-mediated reduction in adiposity and activation of  lipolysis.
Methods
Animal husbandry. Six-week-old C57BL6/J male mice were obtained from Jackson Laboratories. Animals 
were maintained at 22°C ± 2°C on a 12-hour light/dark cycle, with ad libitum access to water and food 
unless otherwise indicated. Three experimental groups were assessed: (a) HFD ad libitum (60% kcal from 
fat, Research Diets, D12492); (b) HFD plus CANA mixed in diet (25 mg/kg/d), fed ad libitum; or (c) HFD, 
weight matched to CANA (WM), achieved via 15%–30% caloric restriction. For the LFD study, mice were 
fed either LFD (10% kcal from fat, Research Diet, D12450J) ad libitum or LFD mixed with CANA (25 
mg/kg/d). Food consumption and body weight were monitored weekly. Mice were sacrificed using pento-
barbital (50–100 mg/kg) after a 4-hour or overnight fast with 4-hour refeeding, as indicated.
FGF21-KO mice were originally generated at Eli Lilly Research Laboratory, as previously report-
ed (32). Briefly, targeted disruption of  the Fgf21 locus resulted in deletion of  the 3′ portion of  exon 
1, all of  exon 2, and the 5′ region of  exon 3. Founder mice were subsequently backcrossed onto the 
C57BL6/J line for at least 10 generations.
Metabolic testing. Oral glucose tolerance tests were conducted after a 16-hour overnight fast and gavage 
with glucose (1 g/kg body weight). For intraperitoneal glucose and pyruvate tolerance tests, mice were 
fasted for 16 hours before injection (2 g/kg glucose, 1 g/kg pyruvate). Blood glucose was measured at indi-
cated time points using the Presto glucometer. Insulin, glucagon, CL316243, and etomoxir responsiveness 
were assessed after a 4-hour fast and injection of  insulin (0.75 U/kg Humulin R, Lilly), glucagon (20 μg/
kg, Lilly), CL316243 (0.1 mg/kg), and etomoxir (15 mg/kg). Resting energy expenditure, VO2, VCO2, food 
intake, and activity were measured in Comprehensive Laboratory Animal Monitoring System as previously 
described (CLAMS, Columbus) (18).
Transcriptomics and PCR. Total RNA was isolated from tissues harvested from mice treated for 4 weeks 
in each of  the 3 experimental groups (n = 3–5 per group) using TRIzol (Life Technologies) and processed 
for hybridization to Affymetrix Mouse ST 2.0 as described previously (45). Real-time quantitative PCR 
was performed using SYBR green detection (Bio-Rad) in a PRISM 7900 Sequence Detection System 
(Applied Biosystem). Primer sequences are listed in Supplemental Table 1. The data were normalized 
using robust multiarray average.
Metabolomics and lipidomics. Tissues harvested after 4 weeks of  treatment were used for analysis of  plas-
ma and liver metabolites, using liquid chromatography–mass spectrometry (LC/MS) to determine metab-
olites, lipid class, and specific lipid content (46). Missing data were imputed with half  of  the minimum 
intensity of  the metabolite, and the imputed data were quantile normalized and log2 transformed.
Serum hormones and liver parameters. Plasma insulin (Crystal Chem, 90080), GLP-1 (Crystal Chem, 81508), 
FGF21 (R&D Systems, MF2100), adiponectin (R&D Systems, MPR300), and glucagon (R&D Systems, 
DGCG) were measured by ELISA. Liver lipids were extracted by chloroform/methanol prior to quantification 
of triglycerides and cholesterol using a colorimetric assay (Cayman Chemical, 10010303, and Cell Biolabs, STA-
384). Liver glycogen was measured following manufacturer’s instructions (MilliporeSigma, MAK016).
Histology. Liver, subcutaneous fat, and pancreas were isolated, weighed, and fixed in 10% buffered for-
malin (Fisher). Paraffin-embedded sections were stained with H&E. Images were captured using a digital 
camera coupled to an optical microscope (Olympus). Steatosis score was assessed at ×20 magnification and 
graded from 0–3: 0 (no steatosis), 1 (<33% of  field), 2 (33%–66%), or 3 (>66%). For islet and adipocyte 
quantification, at least 100 adipocytes and islets were measured from mouse pancreatic or subcutaneous 
adipose sections and quantified using ImageJ (NIH).
Western blotting. Liver samples harvested after 4 weeks of  treatment were homogenized using Tissue-
Lyser (Qiagen) in ice-cold lysis buffer with protease and phosphatase inhibitors (10 mM Na orthovana-
date, 2 mM phenylmethylsulfonyl fluoride, 20 mM leupeptin, 2 mM benzamidine, 1.5 mM aprotinin) 
and spun at 14,000 g for 20 minutes at 4°C. Protein content was measured using a bicinchoninic acid 
(BCA) assay. Liver extracts containing 20 μg protein were separated by SDS-PAGE (4%–12% Bis-Tris 
gel, NuPAGE). Proteins were transferred to nitrocellulose and were blocked with StartingBlock (Thermo 
1 5insight.jci.org   https://doi.org/10.1172/jci.insight.123130
R E S E A R C H  A R T I C L E
Scientific, 37539) prior to overnight incubation at 4°C with primary antibody, as indicated. All anti-
bodies were purchased from Cell Signaling Technologies and used at 1:1000 dilution, unless otherwise 
specified: pAMPK (no. 2535), AMPK (no. 2532), pACC (no. 3661), ACC (no. 3662), pS240/244 s6 (no. 
2215), S6 (no. 2217S), pT308 Akt (no. 9275), pS473 Akt (1:500, no. 9271), Akt (no. 9272), pFoxo1 (no. 
9461), Foxo1 (no. 2880S), pS133 CREB (no. 9191), CREB (no. 9197), pHSL (no. 4139), Hsl (no. 4107), 
and Atgl (no. 2138). After washing in TBS/T, membranes were incubated for 1 hour at room tempera-
ture with HRP-conjugated goat anti-rabbit secondary antibody. Proteins were detected using enhanced 
chemiluminescence (Lumiglo). After stripping with 2-mercaptoethanol, blots were reprobed with anti-β-
actin (no. 3700) or α-tubulin (no. 3873) antibodies. Band intensities were quantified using Image J (NIH).
Bioinformatic analysis. For liver transcriptomics and metabolomics data sets, principal component anal-
ysis revealed that the first principal component was an extraneous source of  variation, so it was accounted 
for as a covariate in linear modeling (47). Metabolomics/lipidomics sample weights were unbiasedly esti-
mated (48) and used in linear modeling. Linear modeling differential analysis was done with the R package 
limma (49). Nominal P values were corrected for multiple testing using the FDR. Transcriptomic pathway 
and transcription factor prediction analysis was done using the Roast method (50), with pathways defined 
by Reactome and TFT database (51).
Statistics. Values are presented as mean ± SEM. Statistical analyses were performed using GraphPad 
Prism 7, using ANOVA followed by Tukey test for comparison of  more than two groups. P < 0.05 was 
considered significant.
Study approval. All experiments were conducted as stated in the NIH Guide for the Care and Use of  Labo-
ratory Animals (National Academy Press, 1996) and approved by the Joslin Diabetes Center and Beth Israel 
Deaconess Medical Center Institutional Animal Care and Use Committees.
Author contributions
SO, CM, and MEP designed the study, generated data, and wrote the manuscript. SO, CM, VS, CK, JCW, 
and YT conducted the experiments. GS provided FGF21-null mice and assisted with the design and imple-
mentation of  the in vivo experiments in FGF21-null mice. JM and RG performed the LC/MS metabolom-
ics experiments and assisted with interpretation. JMD and HP performed the bioinformatics analysis. All 
authors reviewed and edited the manuscript.
Acknowledgments
We are especially grateful to Eleftheria Maratos-Flier for her valuable contributions to studies of  the 
FGF21-KO mice. We thank Grace Daher (Joslin Diabetes Research Center Molecular Phenotyping Core) 
for performing microarray analysis. We thank members of  the Patti lab for helpful discussion. We are grate-
ful for investigator-initiated research support and the supply of  CANA from Janssen Research and Devel-
opment. SO is grateful for funding from the Prince Mahidol Award Foundation under the Royal Patronage. 
We acknowledge support from the Joslin Diabetes Research Center (P30 DK036836).
Address correspondence to: Mary-Elizabeth Patti, Room 620, Joslin Diabetes Center, 1 Joslin Place, Bos-
ton, Massachusetts 02215, USA. Phone: 617.309.1966; Email: mary.elizabeth.patti@joslin.harvard.edu.
 1. Cefalu WT, et al. Efficacy and safety of  canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled 
with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 
2013;382(9896):941–950.
 2. Rosenstock J, et al. Dose-ranging effects of  canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in 
subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–1238.
 3. Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 
2017;377(21):2099.
 4. Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of  ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a 
second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to 
incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors. Clin Drug Investig. 
2016;36(4):313–319.
 5. Ferrannini E, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 
2014;124(2):499–508.
 6. Merovci A, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 
2014;124(2):509–514.
1 6insight.jci.org   https://doi.org/10.1172/jci.insight.123130
R E S E A R C H  A R T I C L E
 7. Daniele G, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care. 
2016;39(11):2036–2041.
 8. Ferrannini E, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects with-
out diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190–1195.
 9. Fralick M, Schneeweiss S, Patorno E. Risk of  diabetic ketoacidosis after initiation of  an SGLT2 inhibitor. N Engl J Med. 
2017;376(23):2300–2302.
 10. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with 
SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638–1642.
 11. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibi-
tion. Diabetes Care. 2015;38(9):1730–1735.
 12. Hohendorff  J, et al. A single dose of  dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MO-
DY than in type 2 diabetes mellitus. Endocrine. 2017;57(2):272–279.
 13. Long JZ, et al. The secreted enzyme PM20D1 regulates lipidated amino acid uncouplers of  mitochondria. Cell. 
2016;166(2):424–435.
 14. Roberts LD, et al. β-Aminoisobutyric acid induces browning of  white fat and hepatic β-oxidation and is inversely correlated 
with cardiometabolic risk factors. Cell Metab. 2014;19(1):96–108.
 15. Hawley SA, et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function 
and increasing cellular AMP levels. Diabetes. 2016;65(9):2784–2794.
 16. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by 
PPARalpha and is a key mediator of  hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426–437.
 17. Owen BM, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 
2014;20(4):670–677.
 18. Douris N, et al. Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology. 
2015;156(7):2470–2481.
 19. Douris N, et al. Beta-adrenergic receptors are critical for weight loss but not for other metabolic adaptations to the consumption 
of  a ketogenic diet in male mice. Mol Metab. 2017;6(8):854–862.
 20. Shin AC, et al. Brain insulin lowers circulating BCAA levels by inducing hepatic BCAA catabolism. Cell Metab. 2014;20(5):898–909.
 21. Maida A, et al. Repletion of  branched chain amino acids reverses mTORC1 signaling but not improved metabolism during 
dietary protein dilution. Mol Metab. 2017;6(8):873–881.
 22. Nogiec C, Burkart A, Dreyfuss JM, Lerin C, Kasif  S, Patti ME. Metabolic modeling of  muscle metabolism identifies key reac-
tions linked to insulin resistance phenotypes. Mol Metab. 2015;4(3):151–163.
 23. Rhee EP, et al. Lipid profiling identifies a triacylglycerol signature of  insulin resistance and improves diabetes prediction in 
humans. J Clin Invest. 2011;121(4):1402–1411.
 24. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 
2010;375(9733):2267–2277.
 25. Hardivillé S, Hart GW. Nutrient regulation of  signaling, transcription, and cell physiology by O-GlcNAcylation. Cell Metab. 
2014;20(2):208–213.
 26. Iroz A, et al. A specific ChREBP and PPARα cross-talk is required for the glucose-mediated FGF21 response. Cell Rep. 
2017;21(2):403–416.
 27. Jois T, et al. Deletion of  hepatic carbohydrate response element binding protein (ChREBP) impairs glucose homeostasis and 
hepatic insulin sensitivity in mice. Mol Metab. 2017;6(11):1381–1394.
 28. Bonner C, et al. Inhibition of  the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secre-
tion. Nat Med. 2015;21(5):512–517.
 29. Wang MY, et al. Dapagliflozin suppresses glucagon signaling in rodent models of  diabetes. Proc Natl Acad Sci USA. 
2017;114(25):6611–6616.
 30. Xu L, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin 
resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149.
 31. Inagaki T, et al. Endocrine regulation of  the fasting response by PPARalpha-mediated induction of  fibroblast growth factor 21. 
Cell Metab. 2007;5(6):415–425.
 32. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate 
impaired adaptation to ketosis. Endocrinology. 2009;150(11):4931–4940.
 33. Bookout AL, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med. 
2013;19(9):1147–1152.
 34. Coskun T, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149(12):6018–6027.
 35. Ding X, et al. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012;16(3):387–393.
 36. Huang Z, et al. The FGF21-CCL11 axis mediates beiging of  white adipose tissues by coupling sympathetic nervous system to 
type 2 immunity. Cell Metab. 2017;26(3):493–508.e4.
 37. Fisher FM, et al. FGF21 regulates PGC-1α and browning of  white adipose tissues in adaptive thermogenesis. Genes Dev. 
2012;26(3):271–281.
 38. Robles-Valdes C, McGarry JD, Foster DW. Maternal-fetal carnitine relationship and neonatal ketosis in the rat. J Biol Chem. 
1976;251(19):6007–6012.
 39. Izumida Y, et al. Glycogen shortage during fasting triggers liver-brain-adipose neurocircuitry to facilitate fat utilization. Nat 
Commun. 2013;4:2316.
 40. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation 
by ageing. Nature. 2010;468(7327):1100–1104.
 41. Hirschey MD, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 
2010;464(7285):121–125.
 42. von Meyenn F, et al. Glucagon-induced acetylation of  Foxa2 regulates hepatic lipid metabolism. Cell Metab. 2013;17(3):436–447.
1 7insight.jci.org   https://doi.org/10.1172/jci.insight.123130
R E S E A R C H  A R T I C L E
 43. Gut P, Verdin E. The nexus of  chromatin regulation and intermediary metabolism. Nature. 2013;502(7472):489–498.
 44. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the 
AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA. 2010;107(28):12553–12558.
 45. Jin W, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of  insulin resistance. J 
Clin Invest. 2011;121(3):918–929.
 46. Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol. 2012;98(1):30.2.1–30.2.24.
 47. Leek JT, et al. Tackling the widespread and critical impact of  batch effects in high-throughput data. Nat Rev Genet. 
2010;11(10):733–739.
 48. Ritchie ME, et al. Empirical array quality weights in the analysis of  microarray data. BMC Bioinformatics. 2006;7:261.
 49. Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 
2015;43(7):e47.
 50. Wu D, Lim E, Vaillant F, Asselin-Labat ML, Visvader JE, Smyth GK. ROAST: rotation gene set tests for complex microarray 
experiments. Bioinformatics. 2010;26(17):2176–2182.
 51. Fabregat A, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2018;46(D1):D649–D655.
